Prenetics Group (PRE) AI Stock Analysis

• Market Cap: $163.84M
• Dividend Yield: N/A
• Average Volume (3M): 99.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: 135.15%
• EPS Growth: 10.32%
• Country: US
• Employees: 285
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.82
• Shares Outstanding: 11,453,009
• 10 Day Avg. Volume: 153,177
• 30 Day Avg. Volume: 99,262
• PEG Ratio: 0.05
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 2.41
• P/FCF Ratio: -2.46
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 2.86
• Enterprise Value/Gross Profit: 5.69
• Enterprise Value/Ebitda: -1.60
• 1Y Price Target: $12.50
• Price Target Upside: -0.56% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: $12.50 ▼(-0.56% Downside)

Prenetics Group's overall stock score is primarily impacted by its financial performance challenges, including negative net income and cash flow issues. While technical analysis shows positive momentum, the valuation remains unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Prenetics Group Business Overview & Revenue Model

Company Description

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

How the Company Makes Money

Prenetics generates revenue primarily through its genetic testing services and health solutions. Key revenue streams include direct-to-consumer sales of genetic testing kits, corporate wellness programs, and partnerships with healthcare providers and insurers. Additionally, Prenetics has established significant collaborations with various organizations to offer their testing solutions, which further expands their market reach and drives earnings. The company also leverages technology through its digital platforms, allowing for subscription-based models and one-time service fees, contributing to a diversified revenue base.

Prenetics Group Financial Statement Overview

Summary

Prenetics Group faces significant profitability challenges, with negative net income and cash flow issues. Despite a strong equity base and low leverage, the company needs to improve its cash flow and profitability metrics to enhance financial health.

Income Statement

Prenetics Group has seen fluctuating revenue growth, with recent declines from 2022 to 2023 but a recovery in 2024. Gross profit margin stands at roughly 50%, indicating strong cost management. However, negative EBIT and net income margins highlight ongoing profitability challenges that could impact long-term sustainability.

Balance Sheet

The company maintains a strong equity position with a positive equity ratio, indicative of low leverage and financial stability. The debt-to-equity ratio remains low, though high negative net income affects return on equity. Overall, the balance sheet suggests a relatively stable financial footing but with profitability concerns.

Cash Flow

Operating cash flow remains negative, suggesting challenges in generating cash from operations. Despite this, there is a positive trend in cash flow from investing activities. The free cash flow remains negative, impacting the company's ability to finance operations without external funding. Overall, cash flow management needs improvement.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.62M	21.74M	275.76M	275.85M	65.18M
Gross Profit	15.40M	8.83M	131.55M	106.13M	26.34M
EBITDA	-51.57M	-47.90M	-214.28M	-157.70M	-1.42M
Net Income	-46.30M	-62.72M	-190.45M	-174.02M	-1.96M
Balance Sheet
Total Assets	213.57M	254.17M	307.98M	148.51M	78.88M
Cash, Cash Equivalents and Short-Term Investments	62.81M	72.74M	164.20M	45.19M	14.49M
Total Debt	5.77M	2.37M	6.65M	5.27M	1.67M
Total Liabilities	42.23M	44.01M	67.94M	549.40M	47.88M
Stockholders Equity	170.39M	206.36M	237.06M	-400.81M	31.08M
Cash Flow
Free Cash Flow	-29.94M	-14.68M	8.17M	2.00M	-5.94M
Operating Cash Flow	-28.87M	-13.76M	14.51M	13.42M	-2.88M
Investing Cash Flow	38.54M	-82.95M	-46.14M	-22.02M	-5.97M
Financing Cash Flow	-3.34M	-4.70M	143.32M	29.32M	11.84M

Prenetics Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.57
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRE, the sentiment is Positive. The current price of 12.57 is above the 20-day moving average (MA) of 10.49, above the 50-day MA of 8.86, and above the 200-day MA of 6.68, indicating a bullish trend. The MACD of 1.33 indicates Negative momentum. The RSI at 71.19 is Negative, neither overbought nor oversold. The STOCH value of 77.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRE.

Prenetics Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRE	53 Neutral	$163.84M	―	-28.29%	―	135.15%	10.32%
BNR	51 Neutral	$96.17M	-4.77	-59.68%	―	5.33%	75.52%
VNRX	45 Neutral	$65.10M	-2.48	73.31%	―	35.10%	39.15%
MYNZ	44 Neutral	$7.10M	―	-358.07%	―	―	―
BDSX	44 Neutral	$62.00M	-1.38	-3609.67%	―	25.70%	39.25%
BNGO	41 Neutral	$16.19M	-0.04	-163.82%	―	-25.02%	85.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Prenetics Group Corporate Events

Prenetics Reports Strong Q2 2025 Growth and Strategic Initiatives

Prenetics Global Limited announced its unaudited financial results for the second quarter of 2025, highlighting significant growth and strategic initiatives. The company’s revenue increased by 594.9% compared to the previous year, driven by the success of its IM8 Health brand, which achieved a compound annual growth rate of over 3,100% since its launch in December 2024. Prenetics aims to reach $100 million in annual recurring revenue by the end of the year and plans to achieve break-even in early 2026. The company also updated its Bitcoin treasury, accumulating 228 Bitcoins as part of its financial strategy. These developments underscore Prenetics’ strong market positioning and commitment to delivering long-term value to its stakeholders.

Prenetics Global Divests ACT Genomics Stake and Invests in Bitcoin

Prenetics Global Limited has announced the divestiture of its 70% interest in ACT Genomics Holdings Company Limited for approximately $46.3 million, marking a significant shift in its operational focus. Additionally, the company has invested $20 million in Bitcoin, acquiring 187.42 Bitcoin at an average price of $106,712 per Bitcoin, reflecting a strategic move to diversify its asset portfolio.

Prenetics Approves Major Share Capital Increase at August 2025 Meeting

On August 1, 2025, Prenetics Global Limited held an Extraordinary General Meeting of Shareholders, where they approved an increase in the company’s authorized share capital from US$50,000 to US$320,000. This decision, supported by a significant majority of shareholders, is expected to provide the company with greater flexibility for future capital raising activities, particularly in support of its Bitcoin treasury strategy and general corporate purposes. The move is anticipated to enhance Prenetics’ strategic opportunities and long-term shareholder value.

Prenetics Announces Shareholder Meeting to Increase Share Capital

On July 18, 2025, Prenetics Global Limited announced an extraordinary general meeting scheduled for August 1, 2025, to discuss increasing its authorized share capital from US$50,000 to US$320,000. This move aims to support the company’s Bitcoin treasury strategy and general corporate purposes, potentially enhancing long-term shareholder value and positioning the company for strategic opportunities.

Prenetics Global Limited Adopts Bitcoin Treasury Strategy Amidst Market Volatility

On July 17, 2025, Prenetics Global Limited announced the adoption of a Bitcoin treasury strategy, having recently completed a $20 million purchase of Bitcoin. This strategy exposes the company to significant risks, including the volatility of Bitcoin prices and potential impacts on financial results and market price of its securities. The strategy, which has not been tested over an extended period, may affect the company’s financial condition and operations due to the inherent risks of holding a concentrated Bitcoin portfolio. Stakeholders are advised to consider these risks, as fluctuations in Bitcoin prices could materially impact the company’s financial outcomes.

Prenetics Global Pioneers Bitcoin Treasury Strategy in Healthcare

On June 18, 2025, Prenetics Global Limited announced its groundbreaking Bitcoin treasury strategy, marking it as the first healthcare company to adopt such an approach. The company purchased $20 million worth of Bitcoin and appointed Andy Cheung, former COO of OKEx, to its Board of Directors to provide strategic oversight. Prenetics aims to leverage its strengthened financial position to become a leader in the intersection of healthcare and digital assets, with plans to accept cryptocurrency payments across its platforms and implement sophisticated alpha-generating strategies. This initiative is supported by Prenetics’ strong business growth and enhanced financial position, positioning the company to benefit from accelerating institutional adoption of digital assets.

Prenetics Sells ACT Genomics to Delta Electronics, Boosts Financial Position

On June 18, 2025, Prenetics Global Limited announced the divestment of its majority stake in ACT Genomics to Delta Electronics, a transaction valued at up to US$71.78 million. This strategic move strengthens Prenetics’ financial position, increasing its cash reserves to approximately US$86 million and short-term assets to US$117 million, while maintaining a debt-free balance sheet. The divestment aligns with Prenetics’ strategy to focus on its high-growth consumer health brands, simplifying its business model and enhancing financial flexibility. The company has raised its FY2025 revenue outlook, driven by the success of its IM8 brand, and is exploring innovative treasury management strategies, including digital assets.

Prenetics Global Limited Appoints New Independent Director to Strengthen Bitcoin Strategy

Prenetics Global Limited announced changes to its Board of Directors, with the term of Ms. Kathryn Henry ending on June 12, 2025, and the appointment of Kong Yiu (Andy) Cheung as an independent director and Audit Committee member effective June 16, 2025. Mr. Cheung, with his extensive experience in digital asset operations and financial technology, is expected to enhance Prenetics’ strategic capabilities, particularly in Bitcoin treasury strategies and digital asset initiatives, as the company explores innovative applications in healthcare.